Enovix Corporation (NASDAQ:ENVX) defied analyst predictions to release its quarterly results, which were ahead of market expectations. It looks like a positive result overall, with revenues of US$7.6m beating forecasts by 9.3%. Statutory losses of US$0.18 per share were 9.3% smaller than the analysts expected, likely helped along by the higher revenues. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Enovix after the latest results.

Taking into account the latest results, the current consensus from Enovix's eleven analysts is for revenues of US$40.4m in 2026. This would reflect a decent 18% increase on its revenue over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to US$0.78. Before this earnings announcement, the analysts had been modelling revenues of US$40.7m and losses of US$0.77 per share in 2026.

As a result, it's unexpected to see that the consensus price target fell 10.0% to US$13.10, with the analysts seemingly becoming more concerned about ongoing losses, despite making no major changes to their forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Enovix at US$25.00 per share, while the most bearish prices it at US$6.00. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Enovix's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Enovix's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 24% growth on an annualised basis. This is compared to a historical growth rate of 61% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 14% annually. So it's pretty clear that, while Enovix's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Enovix's future valuation.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Enovix going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.